Analysis of matrix metalloproteinases (MMPs) in cerebrospinal fluid of patients with amyotrophic lateral sclerosis (ALS)

• Autorzy: Sokołowska B. , Jóźwik A. , Niebroj-Dobosz I. , Janik P. , Kwieciński H.
• Języki publikacji: EN

Abstrakty

EN

Matrix metalloproteinases (MMPs) are implicated in the pathogenesis of motor neuron degeneration in amyotrophic lateral sclerosis (ALS) and might be potential markers of diagnosis, prognosis and monitoring treatment effects. The aim of the present study was evaluation of the MMPs significance in cerebrospinal fluid (CSF MMPs) of patients with ALS in relation to severity of the disease. Metalloproteinases MT-MMP-1, MMP-2, MMP-9 and additionally age of subjects and disease duration were analyzed. The results demonstrate that the error of differentiation between healthy subjects and ALS patients (for MMP-2 feature) as well as between mild and severe ALS states (for CSF MMPs set) equalled to 0.033. In conclusion, the pattern recognition approach may be useful for differentation of ALS progressing on the basis of CSF MMPs features.

Słowa kluczowe

EN

pattern recognition; k-NN classifier; amyotrophic lateral sclerosis; matrix metalloproteinase; cerebrospinal fluid

PL

klasyfikacja K-NN; stwardnienie zanikowe boczne; metaloproteinazy macierzy; płyn mózgowo-rdzeniowy

• Wydawca: University of Silesia, Institute of Informatics, Computer Systems Department
• Czasopismo: Journal of Medical Informatics & Technologies
• Rocznik: 2009
• Tom: Vol. 13
• Strony: 147--150
• Opis fizyczny: Bibliogr. 15 poz., rys., tab.

Twórcy

autor

Sokołowska B.

• Department of Respiratory Research, Medical Research Center, Polish Academy of Sciences, Warsaw, Poland

autor

Jóźwik A.

autor

Niebroj-Dobosz I.

autor

Janik P.

autor

Kwieciński H.

Bibliografia

• [1] BEUCHE W, YUSHCHENKO M, MADER M, MALISZEWSKA M, FELGENHAUER K, WEBER F. Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. NeuroReport 2000; 11: 3419-3422.
• [2] BROOKS BR, MILLER RG, SWASH M, MUNSAT TL. World Federation of Neurology Research Group on Motor Neuron Disease. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis, Amyotrophic Lateral Sclerosis and other Motor Neuron Disorder, 2000, 1: 293-299.
• [3] CUDKOWICZ M, QURESHI M, SHEFNER J. Measures and markers in amyotrophic lateral sclerosis. NeuroRx 2004: 1: 273-283.
• [4] DEVIJVER PA, KITTLER J. Pattern Recognition: A Statistical Approach. Prentice Hall, London, 1982.
• [5] DUDA RO, HART PE, STOCK DG. Pattern Classification. John Wiley and Sons, New York, 2001.
• [6] FIX E, HODGES JL. Discriminatory Analysis: Nonparametric Discrimination Small Sample Performance, project 21-49-004, Report Number 11, USAF School of Aviation Medicine, Randolph Field, Texas, pp. 280-322, 1952, reprinted in the book: Dasarathy BV “NN Pattern Classification Techniques” pp. 40-56, IEEE Computer Society Press, 1991.
• [7] JÓŹWIK A, SERPICO S and ROLI F. A parallel network of modified 1-NN and k-NN classifiers – application to remote-sensing image classification, Patter Recognition Letters 19, pp. 57-62, 1998
• [8] JÓŹWIK A, SOKOŁOWSKA B, NIEBROJ-DOBOSZ I, JANIK P, KWIECIŃSKI H. Pattern recognition approach to differentiation of disease severity in patients with amyotrophic lateral sclerosis, Journal of Medical Informatics & Technologies, 2008; 12: 143-147.
• [9] MURPHY G, NAGASE H. Progress in matrix metalloproteinase research. Molecular Aspects of Medicine 2008; 29: 290-308.
• [10] NAGASE H, VISSE R, MURPHY G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Research 2006; 69: 562-573.
• [11] NIEBROJ-DOBOSZ I, JANIK P, SOKOLOWSKA B, KWIECINSKI H. Matrix metalloproteinases and their inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis (ALS) (in press).
• [12] ROSENBERG GA. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. The Lancet Neurology 2009; 8: 205-216.
• [13] ROWLAND LP, SHNEIDER N. Amyotrophic lateral sclerosis. New England Journal of Medicine 2001; 344 (22): 1688-1700.
• [14] YONG VW, FORSYTH PA, BELL R, KREKOSKI CA, EDWARDS DR. Matrix metalloproteinase and diseases of the CNS. Trends in Neurosciences 1998; 21: 75-80.
• [15] YONG VW, POWER C, FORSYTH P, EDWARDS DR. Metalloproteinases in biology and pathology of the nervous system. Nature Reviews Neuroscience 2001; 2: 502-511.